Q-omics provides the consensus-scored MST1R profile across patient tissues and cancer cell-line models. MST1R expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MST1R is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MST1R RNA expression shows 16,351 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where MST1R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MST1R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MST1R survival associations across molecular data types. MST1R RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MST1R RNA expression–survival associations across cancer types. High MST1R expression shows unfavorable associations in ACC, LUSC and LIHC, but favorable associations in BLCA, UCEC and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MST1R RNA expression.
This table summarizes MST1R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MST1R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MST1R shows lower tumor expression in KIRC and KICH and higher tumor expression in THCA, LUAD, COAD and STAD. The KIRC box plot shows higher MST1R RNA expression in normal versus tumor tissue (log2 FC = −0.725, t-test p < 0.001).
This table shows molecular features associated with MST1R in patient tissues and cancer cell lines. In patient samples, MST1R shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MST1R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_NSCLC_LUAD.
